| Rank |
Status |
Study |
| 1 |
Unknown †
|
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects
| Condition: |
Drug Mechanism |
| Intervention: |
Drug: Lithium Carbonate |
| Outcome Measures: |
Expression levels of genes (known to be regulated by Lithium) analyzed in lymphoblastoid cell cultures established from lymphocytes sampled in healthy volunteers before and after one month of Lithium treatment.; Expression levels of a protein, BDNF (known to be regulated by Lithium) analyzed in lymphoblastoid cell cultures established from lymphocytes sampled in healthy volunteers before and after one month of Lithium treatment.; Enzymatic activity of Complex I (known to be altered by Lithium) analyzed in lymphoblastoid cell cultures established from lymphocytes sampled in healthy volunteers before and after one month of Lithium treatment. |
|
| 2 |
Recruiting
|
Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
| Condition: |
Small Cell Lung Carcinoma |
| Intervention: |
Drug: Lithium Carbonate |
| Outcome Measures: |
Dose-limiting toxicities of Lithium (DLTs), (safety lead-in); Rate of immediate recall memory deterioration at 3 months, (phase II); Rate of immediate recall memory deterioration at 6 and 12 months; Rate of delayed recall memory deterioration at 3, 6 and 12 months; Incidence of brain metastases; Overall survival; Changes in quality-of-life following PCI; Change in hippocampal morphology following Lithium + PCI; Incidence of adverse events; Feasibility of performing serial neurocognitive testing and quality of life exams in patients wit |
|
| 3 |
Recruiting
|
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
| Conditions: |
Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia |
| Interventions: |
Drug: tretinoin; Drug: Lithium carbonate; Other: laboratory biomarker analysis |
| Outcome Measure: |
Maximum tolerated dose of tretinoin when given together with Lithium carbonate, defined as the dose level immediately below that at which at least 2/6 subjects experience dose-limiting toxicity (DLT), graded using the NCI CTCAE version 4.0 |
|
| 4 |
Recruiting
|
Gao Bipolar Spectrum Lithium/Quetiapine Study
| Condition: |
Bipolar Disorder |
| Interventions: |
Drug: Lithium; Drug: Quetiapine |
| Outcome Measures: |
Time to study discontinuation; Lithium vs. Quetiapine effects on general cardiovascular disease risk and role effects on general cardiovascular disease risk and role impairment |
|
| 5 |
Not yet recruiting
|
Lithium for Suicidal Behavior in Mood Disorders
| Conditions: |
Depressive Disorder; Bipolar Disorder; Suicide; Suicide, Attempted |
| Interventions: |
Drug: Lithium; Drug: Placebo |
| Outcome Measure: |
Time to the first repeated episode of suicidal self-directed violence, including suicide attempts, interrupted attempts and hospitalizations for prevention of attempts. |
|
| 6 |
Recruiting
|
Ketamine Plus Lithium in Treatment-Resistant Depression
| Condition: |
Depression |
| Interventions: |
Drug: Ketamine and Lithium; Drug: Ketamine and Placebo |
| Outcome Measures: |
Montgomery Asberg Depression Rating Scale; Quick Inventory of Depressive Symptoms; Patient Rated Inventory of Side Effects (PRISE); Clinical Global Impression; Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) |
|
| 7 |
Unknown †
|
Lithium and Standard Therapy in Resistant Depression
| Condition: |
Depression |
| Interventions: |
Drug: Lithium; Drug: usual care |
| Outcome Measures: |
Suicide completion and acts of deliberate self harm (DSH) will constitute the composite primary outcome; All-cause mortality; Suicide mortality; Deliberate self-harm or attempted suicide; Change in severity of depressive symptoms from baseline; Adverse reactions during the study |
|
| 8 |
Recruiting
|
The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study
| Condition: |
Stroke |
| Intervention: |
Drug: Lithium Carbonate |
| Outcome Measures: |
Increase in total brain gray matter volumes; Cognitive tasks of the Neurological Disorders and Stroke - Canadian Stroke Network's (NINDS-CSN) 30 min. battery; Serum brain-derived neurotrophic factor (BDNF) levels; Serum Lithium and creatinine levels |
|
| 9 |
Not yet recruiting
|
Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode
| Conditions: |
Suicidal Ideation/Behavior; Depression |
| Interventions: |
Drug: Lithium Carbonate; Drug: Placebo |
| Outcome Measures: |
S-STS; C-SSRS |
|
| 10 |
Unknown †
|
The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
| Conditions: |
Bipolar Affective Disorders; Cyclothymic Disorder; Schizoaffective Disorder; Major Depressive Disorder; Dysthymic Disorder; Obsessive-Compulsive Disorder; Panic Disorder; Posttraumatic Stress Disorder; Premenstrual Dysphoric Disorder; Social Anxiety Disorder |
| Intervention: |
|
| Outcome Measures: |
blood levels of Lithium or sertraline; Fluctuations in symptom severity; Correlations between Symptom Severity and Blood Levels of Drugs |
|
| 11 |
Recruiting
|
Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients
| Condition: |
Bipolar I Disorder |
| Interventions: |
Drug: Lithium; Drug: Aripiprazole |
| Outcome Measure: |
The main outcome will be the number of patients that achieve and remain in remission to each treatment at the end of each phase of the study |
|
| 12 |
Not yet recruiting
|
Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma
| Condition: |
Osteosarcoma |
| Intervention: |
Drug: Lithium Carbonate |
| Outcome Measures: |
progression-free survival,incidence of chemotherapy-induced myelosuppression; over-all survival,metastasis-free survival |
|
| 13 |
Recruiting
|
Lithium Augmentation for Hyperarousal Symptoms of Post Traumatic Stress Disorder: Pilot Study
| Conditions: |
Combat Posttraumatic Stess Disorder; Mild Traumatic Brain Injury |
| Intervention: |
Drug: Lithium Carbonate |
| Outcome Measures: |
Udvalg for Kliniske Undersogelser Side Effect Rating Scale; Clinician Administered Posttraumatic Stress Disorder Scale; Beck Scale for Suicide Ideation |
|
| 14 |
Not yet recruiting
|
Lithium Versus Paroxetine in Major Depression
| Condition: |
Major Depressive Disorder |
| Interventions: |
Drug: Lithium; Drug: Paroxetine |
| Outcome Measures: |
Montgomery Asberg Depression Rating Scale (MADRS); The Young Mania Rating Scale (YMRS); The Clinical Global Impression (CGI); The Columbia Suicide Classification Scale; Barnes Akathisia Rating Scale (BARS); Treatment -emergent symptom checklist and questionnaire |
|
| 15 |
Unknown †
|
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
| Conditions: |
Bipolar Disorder; Schizoaffective Disorder |
| Interventions: |
Drug: Olanzapine; Drug: Lithium; Drug: Chlorpromazine |
| Outcome Measures: |
Safety; ¨The frequency of treatment-emergent adverse events (events that first appear or worsen during the study period) will be compared between both groups.; ¨The frequency of side effects as rated with the UKU scale will be compared between both groups.; ¨Weight gain will be compared between both groups.; ¨Frequency of changes in vital signs and laboratory findings will be compared between both groups.; Subjective well being; ¨Total scores on the DAI and the SWN will be compared between both groups.; Adherence; ¨Degree of adherence to the treatment as scored on the MARS will be compared between both groups.; Efficacy; ¨End point analysis: Mean change in various scales from baseline to week 4 and week 8 will be used to compare the efficacy of the two treatments:; ¨Primary efficacy analysis will be assessed by comparing the mean change in theYMRS total score.; ¨Secondary efficacy analysis will be assessed by comparing the mean change in CGI-BP total score and in BPRS total score.; ¨Response analysis: Response is defined as at least a 50% drop in the total YMRS total score from base line to the 8-weeks end point. Euthymia is defined as a total score on the YMRS of no greater than 12 at end point. The number of patients reaching bot; Incidence of depressive episodes; ¨A worsening in the HAMD-21 score of at least 3 points will be used as a definition of a clinically detectable worsening in depressive symptoms.; Six and 12 months outcome; Definition of recovery:; ¨Syndromic recovery: Eight contiguous weeks [50] during which the patient no longer meets criteria for a manic, mixed, or depressive syndrome. Recovery from each of these syndromes is based on DSM-IV criteria and is operationalised as follows: manic synd; ¨Symptomatic recovery: Eight contiguous weeks [50] during which the patient experiences minimal to no psychiatric symptoms, operationalized as follows: Young Mania Rating Scale total score of 5 or less, Hamilton depression scale total score of 10 or les; ¨Relapse: Relapse is defined as the return of symptoms after a remission of less than 8 weeks.; ¨Recurrence: Recurrence is defined as return of symptoms after recovery.; ¨Functional recovery: Return to premorbid levels of function for at least 8 contiguous weeks [50]. To assess functional recovery, seven of the nine general items from the Premorbid Adjustment Scale are evaluated at the 6 and 12-month follow-up visit for |
|
| 16 |
Recruiting
|
Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
| Condition: |
Bipolar Disorder |
| Interventions: |
Drug: Lithium; Drug: Valproate; Drug: Oxcarbazepine; Drug: Quetiapine; Drug: Olanzapine; Drug: Ziprasidone |
| Outcome Measures: |
Change from baseline in Young Mania Rating Scale at 2 weeks and 6 weeks; rate of dropout (treatment discontinuation); Clinical Global Impressions (CGI) Scale; Brief Psychiatric Rating Scale; Global Assessment Scale; Treatment Emergent Symptom Scale; Hamilton Anxiety Rating Scale; Hamilton Depression Rating Scale |
|
| 17 |
Recruiting
|
A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
| Condition: |
Small Cell Lung Cancer |
| Intervention: |
Drug: Lithium |
| Outcome Measures: |
Feasibility of a project design where the patients are randomized into Lithium or placebo; Neurocognition |
|
| 18 |
Recruiting
|
Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain
| Conditions: |
Neuropathic Pain; Neuralgia; Spinal Cord Injuries |
| Interventions: |
Drug: Lithium Carbonate; Drug: Placebo |
| Outcome Measures: |
Change from Baseline in Numeric Rating Scale (NRS) at 24 weeks; Change in multidimensional pain inventory life interference subscale (MPI-LIS); Change in Short-Form 36 single question; Change in Sleep interference assessment score; Change in Weekly number of days with pain attack; Change in the Patient global impression of change (PGIC); Change in PHQ-9; Change in AISA sensory scores, motor scores and AISA impairment scale; Change in Modified Ashworth Scale; Magnetic resonance diffusion tensor imaging (optional); Electrophysiology (optional) |
|
| 19 |
Recruiting
|
Multimodal Neuroimaging of Treatment Effects in Adolescent Mania
| Conditions: |
Mania; Bipolar Disorder |
| Interventions: |
Drug: Quetiapine & Placebo; Drug: Lithium and Placebo; Other: Healthy Controls |
| Outcome Measure: |
The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with Bipolar I disorder (manic or mixed episodes) who are being treated with either quetiapine or Lithium. |
|
| 20 |
Unknown †
|
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
| Condition: |
Medullary Thyroid Cancer |
| Intervention: |
Drug: Lithium carbonate |
| Outcome Measure: |
tumor response rate |
|
